PARP1 and cancer: The deletion or inhibition of eraser enzymes such as PARG may be used to potentiate the synthetic lethality drugs in cancers with mutant phenotypes., and for PARP inhibitor-resistant cancers [43,44,45] or to sensitize cancer chemo- and radiotherapy [46].